Folia Medica Indonesiana
ISSN 0303-7932
Vol. 44 / No. 1 / Published : 2008-01
Order : 13, and page :60 - 66
Related with : Scholar Yahoo! Bing
Original Article :
Review article and clinical experience:the obesity pandemic: the “time-bomb disease” in the future?where have we been? and what should we do?
Author :
- Askandar Tjokroprawiro*1
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Airlangga University School of Medicine, Dr. Soetomo Teaching Hospital, Jl Mayjen Mustopo 6-8, Surabaya
Abstract :
Obesity is a preclinical sign of lifestyle related disease. It is associated with an increased cardiometabolic risk (CMR) factors that appear to directly promote the development of cardiovascular disease (CVD). The Endocannabinoid system (ECS) is an endogenous and physiological system which is important in the control of energy balance and body weight. When the ECS is overactive, additional fat is stored and the risk of insulin resistance, glucose intolerance, elevated triglyceride (TG) levels, and low HDL-C levels is increased. Over activation of the ECS has now been demonstrated in both human obesity and obesity with a predominance of central abdominal adipose tissue. The ESC comprises the CB1 and CB2 receptors and their endogenous ligands, anandamide (AEA) and 2-AG. The activation of the ECS causes hyperphagia, excessive fat accumulation, and increased cardiovascular risk factors. Rimonabant is the first selective CB1-Receptor blocker which eliminates endocannabinoid-induced hyperphagia, lipogenesis, and metabolically improves cardiovascular risk factors; this drug may inhibit nicotine-induced dopamine release leading to smoking cessation. On the basis of preliminary results, rimonabant may be developed for the management of obesity and smoking cessation. Rimonabant can play an important role in reducing obesity-related cardiometabolic risk (CMR) factors.
Keyword :
obesity, cardiometabolic risk (CMR), endocannabinoid system (ECS), CB1 receptor, CB2 receptor, anandamide (AEA), 2-AG, Rimonabant ,
References :
Aronne, LJ,(2007) Is rimonabant a safe and effective treatment for obesity? - : Medical Progress
Cota, D, Marsicano, G, Tschop, M, Gruber, Y et al.,(2003) The endogenous cannabinoid system effects energy balance via central orexigenic drive and peripheral lipogenesis - : The Journal of Clinical Investigation
Archive Article
Cover Media | Content |
---|---|
![]() Volume : 44 / No. : 1 / Pub. : 2008-01 |
|